Pregled bibliografske jedinice broj: 818481
Epigenetic modulation of N-glycome from HepG2 cells
Epigenetic modulation of N-glycome from HepG2 cells // International Symposium on Glycoconjugates (GLYCO 23 XXIII) : abstracts ; u: Glycoconjugate gurnal32 (2015) (5) 173-342 ; No 72 / Lauc, Gordan (ur.).
Split: Springer, 2015. str. 212-213 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 818481 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Epigenetic modulation of N-glycome from HepG2 cells
Autori
Klasić, Marija ; Krištić, Jasminka ; Tadić, Vanja ; Markulin, Dora ; Dobrinić, Paula ; Korać, Petra ; Lauc, Gordan ; Zoldoš, Vlatka
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
International Symposium on Glycoconjugates (GLYCO 23 XXIII) : abstracts ; u: Glycoconjugate gurnal32 (2015) (5) 173-342 ; No 72
/ Lauc, Gordan - Split : Springer, 2015, 212-213
Skup
International Symposium on Glycoconjugates (23 ; 2015)
Mjesto i datum
Split, Hrvatska, 15.09.2015. - 20.09.2015
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
DNA methylation ; N-glycosylation ; DNA methylation inhibitor ; HepG2
Sažetak
Protein N-glycosylation is an important posttranslational modification which affects protein structure and function. A great amount of plasma proteins are synthesized in liver and changes in the plasma glycans are often associated with different types of liver diseases, including hepatocellular carcinoma (HCC). HepG2 cell line is a hepatocellular carcinoma cell line and its secretome is comparable with secretomes of HCC patients. Using different concentrations of DNA methylation inhibitors (5-aza- citidine, 5-aza-2-deoxycitidine and Zebularine) we have induced hypomethylation in HepG2 cells. Following 72h treatment with the inhibitors, HepG2 cell population was evaluated for survival, cell cycle stage, and karyotype changes, and glycans were measured from the HepG2 secretome using HILIC and MS. The treatment with all three epigenetic inhibitors resulted in changed DNA methylation and glyco-gene expression level, as well as in N-glycome composition of HepG2 secretome. The presented work contributes to our understanding of DNA methylation inhibitor efficiency in altering the N-glycan profiles of secreted proteins, but also shows the need for precise dosage of known epigenetic therapies.
Izvorni jezik
Engleski
Znanstvena područja
Biologija
POVEZANOST RADA
Projekti:
315997 - Integrating research in molecular life sciences at the University of Zagreb (INTEGRA-LIFE) (Lauc, Gordan; Zoldoš, Vlatka; Gruić-Sovulj, Ita; Vlahoviček, Kristian; Weygand Đurašević, Ivana; Rokov Plavec, Jasmina; Maravić Vlahoviček, Gordana, EK - FP7-REGPOT-2012-2013-1) ( CroRIS)
FP7- 305479
Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb,
Prirodoslovno-matematički fakultet, Zagreb,
GENOS d.o.o.
Profili:
Marija Klasić
(autor)
Paula Dobrinić
(autor)
Dora Markulin
(autor)
Jasminka Krištić
(autor)
Gordan Lauc
(autor)
Vlatka Zoldoš
(autor)
Vanja Tadić
(autor)
Petra Korać
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE